EXPERIENCE OF TREATMENT WITH LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (RVD) IN THE FIRST LINE IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA IN THE HOSPITALS OF ARAGON AND THE PROVINCE OF SORIA

被引：0
|
作者：
Yus Cebrian, F. [1 ]
Paul Vidaller, P. J. [1 ]
Romero Quezada, L. L. [1 ]
Perella Arnal, M., I [1 ]
Campuzano Saavedra, V [2 ]
Sancho Val, L., I [3 ]
Gonzalez Gomez, N. [4 ]
Marco Amigot, J. J. [5 ]
Murillo Flores, I. M. [5 ]
Carrasco Baraja, V [6 ]
Godoy Molias, A. C. [7 ]
Paricio Moreno, M. [3 ]
Malo Yague, M. [8 ]
Delgado Beltran, M. P. [7 ]
Aguilar Franco, C. [2 ]
Palomera Bernal, L. R. [9 ]
机构：
[1] Hosp Barbastro, Huesca, Huesca, Spain
[2] Hosp Santa Barbara, Puertollano, Spain
[3] Hosp Alcaniz, Alcaniz, Teruel, Spain
[4] Hosp Obispo Polanco, Teruel, Spain
[5] Hosp San Jorge, Huesca, Spain
[6] Hosp Royo Villanova, Zaragoza, Spain
[7] Hosp Miguel Servet, Zaragoza, Spain
[8] Hosp Ernest Lluch, Zaragoza, Spain
[9] Hosp Clin Lozano Blesa, Zaragoza, Spain
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PC-013
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [21] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [22] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dicamillo, Sara
    Roberts, Danielle
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2023, 142
  • [23] A 28 Day Schedule for Lenalidomide Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Chari, Ajai
    Roper, Nitin
    Jagannath, Sundar
    BLOOD, 2011, 118 (21) : 1272 - 1273
  • [24] Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance
    Pasvolsky, Oren
    Milton, Denai R.
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer A.
    Saini, Neeraj Y.
    Lin, Paul
    Siddiqui, Umer R.
    Khan, Hina N.
    Ramdial, Jeremy
    Nieto, Yago
    Tang, Guilin
    Lakhani, Kiran
    Aljawai, Yosra M.
    Kebriaei, Partow
    Lee, Hans C.
    Patel, Krina K.
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2024, 144 : 7018 - 7019
  • [25] Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study
    Kaufman, Jonathan L.
    Shah, Jatin J.
    Laubach, Jacob P.
    Mitchell, Alaina R.
    Sharp, Cathy
    Lewis, Colleen
    Harvey, R. Donald
    Gleason, Charise
    Casbourne, Daniela
    Nooka, Ajay K.
    Heffner, Leonard T.
    Richardson, Paul G.
    Orlowski, Robert Z.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [26] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    A K Nooka
    J L Kaufman
    S Muppidi
    A Langston
    L T Heffner
    C Gleason
    D Casbourne
    D Saxe
    L H Boise
    S Lonial
    Leukemia, 2014, 28 : 690 - 693
  • [27] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    Nooka, A. K.
    Kaufman, J. L.
    Muppidi, S.
    Langston, A.
    Heffner, L. T.
    Gleason, C.
    Casbourne, D.
    Saxe, D.
    Boise, L. H.
    Lonial, S.
    LEUKEMIA, 2014, 28 (03) : 690 - 693
  • [28] Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy
    Medhekar, Rohan
    Ran, Tao
    Fu, Alex Z.
    Patel, Sharmila
    Kaila, Shuchita
    BLOOD, 2021, 138 : 3782 - +
  • [29] Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma
    Cook, Joselle
    Johnson, Isla
    Higgins, Alexandra
    Sidana, Surbhi
    Warsame, Rahma
    Gonsalves, Wilson
    Gertz, Morie A.
    Buadi, Francis
    Lacy, Martha
    Kapoor, Prashant
    Dispenzieri, Angela
    Kourelis, Taxiarchis
    Dingli, David
    Fonder, Amie
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kyle, Robert
    Leung, Nelson
    Go, Ronald
    Rajkumar, Vincent S.
    Kumar, Shaji
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : 330 - 337
  • [30] Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
    Richardson, Paul G.
    Durie, Brian G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Dispenzieri, Angela
    Moreau, Philippe
    Kumar, Shaji
    Raje, Noopur
    Munshi, Nikhil
    Laubach, Jacob P.
    O'Gorman, Peter
    O'Donnell, Elizabeth
    Voorhees, Peter
    Facon, Thierry
    Blade, Joan
    Lonial, Sagar
    Perrot, Aurore
    Anderson, Kenneth C.
    HAEMATOLOGICA, 2023, 108 (11) : 2894 - 2912
12345